Therapeutic Asset Ratings
9,928 results matching 1 filter
91,564
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Etoposide
Human T-Lymphotropic Virus 1 Infectious Disease
National Cancer Institute (NCI)
P1
CC
(43)
Etoposide
Bladder Transitional Cell Carcinoma
Jonsson Comprehensive Cancer Center
P1
CC
(43)
Etoposide
Urethra Transitional Cell Carcinoma
Jonsson Comprehensive Cancer Center
P1
CC
(43)
Etoposide
Primary Brain Neoplasm
Theodore S. Johnson
P1
CC
(43)
Etoposide
Prostate Small Cell Carcinoma
Jonsson Comprehensive Cancer Center
P1
CC
(43)
Etoposide
Lymphoplasmacytic Lymphoma
City of Hope Medical Center
P1
CC
(43)
Etoposide
Urinary Bladder Cancer
Jonsson Comprehensive Cancer Center
P1
CC
(43)
Etoposide
Urethra Cancer
Jonsson Comprehensive Cancer Center
P1
CC
(43)
Etoposide
Stage IVb Bladder Cancer
Jonsson Comprehensive Cancer Center
P1
CC
(43)
Etoposide
Ureter Small Cell Carcinoma
Jonsson Comprehensive Cancer Center
P1
CC
(43)
Et-Stem
Frontotemporal Dementia
Samsung Medical Center
P1
CC
(43)
Everolimus
Amyotrophic Lateral Sclerosis Type 19
M.D. Anderson Cancer Center
P1
CC
(43)
evm14
Squamous Cell Lung Carcinoma
Everest Medicines (Beijing) Co., Ltd.
P1
CC
(43)
Evolve104
Anal Squamous Cell Carcinoma
EvolveImmune United, Inc
P1
CC
(43)
Evolve104
Cervical Squamous Cell Carcinoma
EvolveImmune United, Inc
P1
CC
(43)
Evolve104
Skin Squamous Cell Carcinoma
EvolveImmune United, Inc
P1
CC
(43)
Evolve104
Squamous Cell Carcinoma Of Penis
EvolveImmune United, Inc
P1
CC
(43)
Evolve104
Squamous Cell Lung Carcinoma
EvolveImmune United, Inc
P1
CC
(43)
Evolve104
Urethra Squamous Cell Carcinoma
EvolveImmune United, Inc
P1
CC
(43)
Evolve104
Vulvar Squamous Cell Carcinoma
EvolveImmune United, Inc
P1
CC
(43)
Evuzamitide
Cryopyrin-Associated Periodic Syndrome
National Institute of Allergy and Infectious Diseases (NIAID)
P1
CC
(43)
Exemestane
Tuberous Sclerosis
SAPU NANO (US) LLC
P1
CC
(43)
Exercise Mobilized Prophylactic Dli
Acute Lymphoblastic Leukemia
University of Arizona
P1
CC
(43)
Exercise Mobilized Prophylactic Dli
Acute Undifferentiated Leukemia
University of Arizona
P1
CC
(43)
exs73565
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
P1
CC
(43)
Showing 2001 to 2025 of 9,928 assets
Previous
Page 81 of 398
Next